abstract BACKGROUND AND OBJECTIVE: Previous research suggests an association of celiac disease (CD) with anorexia nervosa (AN), but data are mostly limited to case reports. We aimed to determine whether CD is associated with the diagnosis of AN.
Celiac disease (CD) is an inflammatory disorder in which gluten ingestion causes smallintestinal villous atrophy; the treatment consists of a lifelong strict adherence to a gluten-free diet. 1 The disease occurs in 1% to 2% of the Western population 2 and is more prevalent in women. Common presenting symptoms include gastrointestinal complaints, loss of appetite, fatigue, and, in children, stunted growth and pubertal delay. 3 There are also numerous extraintestinal manifestations of CD, including psychiatric comorbidity. 4 Anorexia nervosa (AN) is an eating disorder associated with underweight, fear of weight gain, and disturbance in the way in which one's body weight or shape is experienced, undue influence of body weight on self-evaluation, or persistent lack of recognition of the seriousness of the low weight. 5 The disorder typically affects girls during adolescence and young adulthood and is associated with elevated psychiatric and somatic morbidity and mortality. 6 Diseases with dietary constraints, such as food allergy and type 1 diabetes, 7, 8 have been associated with AN. It is conceivable that a restrictive diet, in susceptible individuals, may trigger obsessive eating patterns; for others, the diet may cause a prolonged negative energy balance that could be the tipping point for developing AN. 9 Previous research has indicated that AN may be linked to CD, but data have mostly been limited to case reports. 10 -16 The only earlier population-based study in this field found CD to be associated with a significant two-to-threefold increased diagnosis of AN and vice versa. 17 However, that study was restricted to patients requiring hospital admission for CD and may therefore have included patients with a high degree of comorbidity, which may have caused exaggerated risk estimates.
The primary aim of this nationwide study was to test the hypothesis that individuals with biopsyverified CD were at increased risk of AN before or after CD diagnosis. Our secondary aim was to examine if any observed association with AN diagnosis was specific to CD or also present in patients with milder small-intestinal histopathology. We therefore examined the association of diagnosed AN also among biopsied individuals without CD.
MeThODs
Using the personal identity number 18 assigned to all Swedish residents, we linked histopathology data on individuals undergoing smallintestinal biopsy to the National Patient Register 19 to determine their risk for AN diagnosis compared with population-based matched controls.
study sample
Individuals with CD, defined as the presence of small-intestinal villous atrophy (Marsh grade III), 20 were identified by using the computerized histopathology records of Sweden's 28 pathology departments; an earlier evaluation has shown that 95% of Swedish individuals with villous atrophy have a clinical CD diagnosis. 21 The time of diagnosis was defined as the time of smallintestinal biopsy, ranging from 1969 to 2008. 18 We also identified individuals undergoing biopsy showing smallintestinal inflammation (Marsh grade I-II) or normal mucosa (Marsh grade 0) but with a positive CD serology test (antigliadin, antiendomysial, or transglutaminase antibodies). 22 Data on CD serology originated from 8 university hospitals providing care for approximately half of the Swedish population. 22 By using the same dataset as previously reported, 23 27 We also retrieved information on type 1 diabetes diagnosis as recorded in the National Patient Register by age 30 years (ICD-8/ICD-9, 250; ICD-10, E10). We used an age cutoff because ICD-8 and ICD-9 do not distinguish between type 1 and type 2 diabetes. Covariates are categorized as shown in Table 1 .
statistical analyses
The associations of the diagnosis of AN were estimated by using Cox regression and logistic regression models for matched data.
Cox Regression: Subsequent Diagnosis of AN After CD
We used stratified Cox proportionalhazards regression, with age in days as the time metric, to estimate hazard ratios (HRs) for incident diagnosis of AN with associated 95% confidence intervals (CIs). The HRs were modeled separately within each stratum consisting of 1 woman undergoing biopsy and up to 5 matched controls; this stratumwise analysis eliminates the effect of the matching variables (ie, age, sex, calendar period of birth, and county of residence). Individuals were followed from January 1, 1987, or birth for children born thereafter, until AN diagnosis, emigration, death, or December 31, 2009, whichever occurred first. The follow-up started in 1987, when the National Patient Register became nationwide, for all participants at risk for AN. We excluded 73 individuals diagnosed with AN before 1987 (start of follow-up) and 319 with a record 3
FIGuRe 1
Flowchart illustrating the formation of the study sample. Individuals undergoing small-intestinal biopsy were identified by using the computerized histopathology records of Sweden's pathology departments. The study sample was restricted to women living in Sweden in 1987 (when the National Patient Register became nationwide) and later. In a post hoc analysis, we also examined AN and CD in men (CD, n = 11 025; controls, n = 54 774).
Statistical significance was defined as 95% CIs for HRs and ORs not including 1.00. Data were analyzed by using Stata version 14 (Stata Corp, College Station, TX).
ethics
This study was approved by the Regional Ethical Vetting Board in Stockholm, Sweden, which deemed that individual informed consent was not required. 29 Data used in this study were deidentified.
ResuLTs
Among the 17 959 women with CD in this study, the median age at CD diagnosis was 28 years (interquartile range, 6-52 years) (see Table 1 
an in biopsied Patients Without cD
In secondary analyses, we tested the association of AN with (1) smallintestinal inflammation without villous atrophy and (2) normal small-intestinal mucosa, but with positive CD serology. Both groups had a significantly increased risk for diagnosis of AN before as well as after the time of biopsy compared with matched controls (Tables 2  and 3 ).
Post hoc analysis: an and cD in Men
There was no significantly increased risk for subsequent AN among males with CD (HR, 0.95; 95% CI, 0.21-4.32). This HR was based on 12 men being diagnosed with AN. Nor did we find a significantly increased OR for previous AN among men with CD (OR, 2.50; 95% CI, 0.63-10.00).
DIscussIOn
This nationwide study found a positive association between CD and AN both before and after CD diagnosis. This bidirectional association should encourage physicians to closely monitor these patients and calls for heightened understanding of factors that contribute to their cooccurrence.
Potential Mechanisms of action
We propose that a number of factors may contribute to this bidirectional association. 
clinical Relevance
The positive association of CD with AN, both before and after CD diagnosis, should spur a careful initial assessment and follow-up of these illnesses. It should also be appreciated that the 2 conditions can complicate each other. Having AN makes it harder to follow a gluten-free diet, and it cannot be excluded that some AN patients knowingly consume gluten-containing products to lose weight. 11 The treatment of AN and CD require different competences and a multidisciplinary approach to management is important.
Although the vast majority of AN occurs in women, this disease can also occur in men. Although we 6
FIGuRe 3
OR for AN before CD diagnosis. Participants were matched for age, sex, calendar period of birth, and county of residence. Adjusted analyses accounted for education level, socioeconomic status, and type 1 diabetes. found no significant association between AN and CD in men, this does not mean that the risk of CD is different in women and men with AN. Our male-restricted analysis had low statistical power, and we urge caution when interpreting those findings.
comparison With earlier Literature
Research on CD and AN almost exclusively consists of case-series. 10 -15 The largest case series so far was published by Leffler et al 11 in 2007 and included 10 female patients with CD and eating disorders. All patients in this study were first diagnosed with AN or bulimia nervosa and only later with CD. Only 1 previous study by Basso et al 16 specifically screened for CD in patients with AN; 1 out of 177 (0.6%) screened patients with AN had biopsy-verified CD, but this study was unable to calculate any relative risk estimates because it had no control group, nor did the investigators examine the temporality between CD and AN.
Recently, however, an English register-based study, including hospitalized AN patients, found a significant threefold increased risk of later CD diagnosis and a twofold risk increase for AN in CD patients. 17 Although that study identified patients requiring hospital admission for CD, our study includes both in-and outpatients with CD. This distinction may be important because inpatient registers are often limited to patients with more severe CD and more susceptible to surveillance bias, which could overinflate risk estimates.
strengths and Limitations
The main strength of our paper is the population-based approach with almost 18 000 CD patients. The large numbers allowed us to examine subsets of patents with CD stratified by age and calendar period of diagnosis.
We used small-intestinal biopsy reports with villous atrophy to identify individuals with CD. Throughout the study period, biopsy was the gold standard for CD diagnosis, and >96% of Swedish pediatric and adult gastroenterologists performed a biopsy before assigning a CD diagnosis. 21 Non-celiac causes for villous atrophy are uncommon in Sweden, and when we examined 114 randomly selected charts of patients with villous atrophy, 108 (95%) had CD. 21 In a subset of patients with available data at the time of CD diagnosis, 88% were positive for either transglutaminase, endomysium, or antigliadin antibodies. Of note, a large proportion of patients in our sample were diagnosed when gliadin was the only available antibody and before transglutaminase and endomysium antibodies were readily available in the clinic.
Although we are unaware of any validation of AN as registered in the National Patient Register (and we did not have access to medical records to verify the AN diagnoses), the overall validity of this register is high with 85% to 95% of diagnoses being correct. 19 To increase the specificity of the AN diagnosis, we carried out a sensitivity analysis restricting our outcome to individuals with AN listed as the main diagnosis. This analysis also showed a positive association, although the HR was somewhat lower (1.34 vs 1.46 for our main analysis) and was not statistically significant.
This study has some limitations. We did not screen for undiagnosed CD or subthreshold AN. It is therefore likely that some individuals with long-standing eating disturbances were first screened for CD, and then subsequently diagnosed with AN only when the gluten-free diet did not help. A related limitation is our lack of clinical data on symptoms or signs that would enable us to differentiate between subtypes of AN or differences in CD presentation. Moreover, in patients with an initial diagnosis of AN followed by a subsequent diagnosis of CD, it is also possible that the AN diagnosis may represent a misdiagnosis of CD. In our earlier validation study of CD, 21 1 in 3 patients with CD suffered from weight loss or growth failure, which are symptoms resembling AN. It is not likely that the association is due to gastrointestinal changes in AN patients being misinterpreted as CD on biopsy. Not even AN with severe underweight has demonstrated mucosal atrophy. 10, 32 In addition, data on ethnicity and diet were lacking. The latter prevented us from studying whether strict adherence to a gluten-free diet mediated the association with AN. 
cOncLusIOns
The bidirectional association between diagnosis of AN and CD warrants attention in the initial assessment and the follow-up of women with these illnesses. This is important because the presentation of these conditions may mimic each other and the misdiagnosis of either disorder likely causes protracted and unnecessary morbidity.
